Martin Roatsch

PhD Student
(Alumni)

Albert-Ludwigs-University of Freiburg
Institute of Pharmaceutical Sciences

2016 PhD thesis, Albert-Ludwigs-University of Freiburg
2012 - 2016 PhD student in the Lab of Prof. Dr. Manfred Jung, Institute of Pharmaceutical Sciences (Medicinal Chemistry), Albert-Ludwigs-University of Freiburg
2011 Master of Science (summa cum laude)
2010 Erasmus Semester at École Nationale Supérieure de Chimie de Montpellier (ENSCM), Montpellier, France
2009 - 2011 Studies of Chemistry (M.Sc.), University of Leipzig
2009 Bachelor of Science (summa cum laude)
2006 - 2009 Studies of Chemistry (B.Sc.), University of Leipzig

Awards, scholarships

since 2013 PhD Scholarship of the Studienstiftung des deutschen Volkes
2006 - 2011 Scholarship of the Studienstiftung des deutschen Volkes

Publications

  • Morera L., Roatsch M., Furst M.C., Hoffmann I., Senger J., Hau M., Franz H., Schule R., Heinrich M.R. and Jung M. (2016) 4-Biphenylalanine- and 3-Phenyltyrosine-Derived Hydroxamic Acids as Inhibitors of the JumonjiC-Domain-Containing Histone Demethylase KDM4A. ChemMedChem doi: 10.1002/cmdc.201600218
  • Roatsch M., Robaa D., Pippel M., Nettleship J.E., Reddivari Y., Bird L.E., Hoffmann I., Franz H., Owens R.J., Schule R., Flaig R., Sippl W. and Jung M. (2016) Substituted 2-(2-aminopyrimidin-4-yl)pyridine-4-carboxylates as potent inhibitors of JumonjiC domain-containing histone demethylases. Future Med Chem [epub ahead of print]
  • Ruger N., Roatsch M., Emmrich T., Franz H., Schule R., Jung M. and Link A. (2015) Tetrazolylhydrazides as Selective Fragment-Like Inhibitors of the JumonjiC-Domain-Containing Histone Demethylase KDM4A. ChemMedChem 10, 1875-1883.
  • Discovery of Histone Demethylase Inhibitors. A.-T. Hauser, M. Roatsch, J. Schulz-Fincke, D. Robaa, W. Sippl, M. Jung; Epigenetic Technological Applications (Ed.: Y. G. Zheng), Academic Press (2015) Chapter 18, pages 397-424
  • Hoffmann I., Roatsch M., Schmitt M.L., Carlino L., Pippel M., Sippl W. and Jung M. (2012) The role of histone demethylases in cancer therapy. Mol. Oncol 6, 683-703.